Noonan syndrome, the Ras-MAPK signalling pathway and short stature

Hormone Research

Volumn 71, Issue SUPPL. 2, 2009, Pages 64-70

  Binder, Gerhard ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

GH therapy; Noonan syndrome; Ras MAPK signaling; Short stature; Tumour risk

Indexed keywords

B RAF KINASE; GROWTH HORMONE; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE 1B; PROTEIN TYROSINE PHOSPHATASE SHP 2; RAS PROTEIN; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; SOS PROTEIN;

ACUTE MYELOBLASTIC LEUKEMIA; AMINO ACID SUBSTITUTION; CANCER RISK; CANCER SUSCEPTIBILITY; COMORBIDITY; CONFERENCE PAPER; COSTELLO SYNDROME; DOWN REGULATION; FOOD AND DRUG ADMINISTRATION; GENE; GENE FREQUENCY; GENE MUTATION; GENE SEGREGATION; GENETIC LINKAGE; GROWTH DISORDER; GROWTH HORMONE BLOOD LEVEL; HUMAN; LINKAGE ANALYSIS; MISSENSE MUTATION; MOLECULAR GENETICS; NOONAN SYNDROME; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REGULATORY MECHANISM; SHORT STATURE; SIGNAL TRANSDUCTION; THERAPY EFFECT; TREATMENT RESPONSE;

CARRIER PROTEINS; DOWN-REGULATION; HUMANS; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MUTATION; NEOPLASMS; NOONAN SYNDROME; ONCOGENE PROTEIN P21(RAS); PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 11; RISK FACTORS;

EID: 66749151333     PISSN: 03010163     EISSN: None     Source Type: Journal    
DOI: 10.1159/000192439     Document Type: Conference Paper

References (36)

1. Noonan JA, Ehmke DA: Associated non cardiac malformations in children with congenital heart disease. J Pediatr 1963;63:468-470.
2. van der Burgt I, Berends E, Lommen E, van Beersum S, Hamel B, Mariman E: Clinical and molecular studies in a large Dutch family with Noonan syndrome. Am J Med Genet 1994;53:187-191.
3. Roberts A, Allanson J, Jadico SK, Kavamura MI, Noonan J, Opitz JM, Young T, Neri G: The cardiofaciocutaneous syndrome. J Med Genet 2006;43:833-842.
4. Aoki Y, Niihori T, Kawame H, Kurosawa K, Ohashi H, Tanaka Y, Filocamo M, Kato K, Suzuki Y, Kure S, Matsubara Y: Germline mutations in HRAS pro to-oncogene cause Costello syndrome. Nat Genet 2005; 37: 1038-1040.
5. Nora JJ, Sinha AK: Direct familial transmission of the Turner phenotype. Am J Dis Child 1968;116:343-350.
6. Jamieson CR, van der Burgt I, Brady AF, van Reen M, Elsawi MM, Hoi F, Jeffery S, Patton MA, Mariman E: Mapping a gene for Noonan syndrome to the longarm of chromosome 12. Nat Genet 1994;8:357-360.
7. Tartaglia M, Mehler EL, Goldberg R, Zampino G, Brunner HG, Kremer H, van der Burgt I, Crosby AH, Ion A, Jeffery S, Kalidas K, Patton MA, Kucherlapati RS, Gelb BD: Mutations in PTPN11, encodingthe protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet 2001;29:465-468.
8. Schubbert S, Zenker M, Rowe SL, Boll S, Klein C, Bollag G, van der Burgt I, Musante L, Kalscheuer V, Wehner LE, Nguyen H, West B, Zhang KY, Sistermans E, Rauch A, Niemeyer CM, Shannon K, Kratz CP: Germline KRAS mutations cause Noonan syndrome. Nat Genet 2006;38:331-336.
9. Tartaglia M, Pennacchio LA, Zhao C, Yadav KK, Fodale V, Sarkozy A, Pandit B, Oishi K, Martinelli S, Schackwitz W, Ustaszewska A, Martin J, Bristow J, Carta C, Lepri F, Neri C, Vasta I, Gibson K, Curry CJ, Siguero JP, Digilio MC, Zampino G, Dallapiccola B, Bar-Sagi D, Gelb BD: Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome. Nat Genet 2007;39:75-79.
10. Roberts AE, Araki T, Swanson KD, Montgomery KT, Schiripo TA, Joshi VA, Li L, Yassin Y, Tamburino AM, Neel BG, Kucherlapati RS: Germline gain-of-function mutations in SOS1 cause Noonan syndrome. Nat Genet 2007;39:70-74.
11. Razzaque MA, Nishizawa T, Komoike Y, Yagi H, Furutani M, Amo R, Kamisago M, Momma K, Katayama H, Nakagawa M, Fujiwara Y, Matsushima M, Mizuno K, Tokuyama M, Hirota H, Muneuchi J, Higashinakagawa T, Matsuoka R: Germline gain-of-function mutations in RAF1 cause Noonan syndrome. Nat Genet 2007;39:1013-1017.
12. Pandit B, Sarkozy A, Pennacchio LA, Carta C, Oishi K, Martinelli S, Pogna EA, Schackwitz W, Ustaszewska A, Landstrom A, Bos JM, Ommen SR, Esposito G, Lepri F, Faul C, Mundel P, López Siguero JP, Tenconi R, Selicorni A, Rossi C, Mazzanti L, Torrente I, Marino B, Digilio MC, Zampino G, Ackerman MJ, Dallapiccola B, Tartaglia M, Gelb BD: Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy. Nat Genet 2007; 39:1007-1012.
13. Araki T, Mohi MG, Ismat FA, Bronson RT, Williams IR, Kutok JL, Yang W, Pao LI, Gilliland DG, Epstein JA, Neel BG: Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpnll mutation. Nat Med 2004;10:849-857.
14. Rodriguez-Viciana P, Tetsu O, Tidyman WE, Estep AL, Conger BA, Cruz MS, McCormick F, Rauen KA: Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome. Science 2006; 311:1287-1290.
15. Zenker M, Horn D, Wieczorek D, Allanson J, Pauli S, van der Burgt I, Doerr HG, Caspar H, Hofbeck M, Gillessen-Kaesbach G, Koch A, Meinecke P, Mundlos S, Nowka A, Rauch A, Reif S, von Schnakenburg C, Seidel H, Wehner LE, Zweier C, Bauhuber S, Matejas V, Kratz CP, Thomas C, Kutsche K: SOS1 is the second most common Noonan gene but plays no major role in cardio-facio-cutaneous syndrome. J Med Genet 2007;44:651-656.
16. Jongmans M, Sistermans EA, Rikken A, Nillesen WM, Tamminga R, Patton M, Maier EM, Tartaglia M, Noordam K, van der Burgt I: Genotypic and phenotypic characterization of Noonan syndrome: new data and review of the literature. Am J Med Genet 2005;134:165-170.
17. Ranke MB, Heidemann P, Knupfer C, Enders H, Schmaltz AA, Bierich JR: Noonan syndrome: growth and clinical manifestations in 144 cases. Eur J Pediatr 1988; 148:220-227.
18. Shaw AC, Kalidas K, Crosby AH, Jeffery S, Patton MA: The natural history of Noonan syndrome: a long-term follow-up study. Arch Dis Child 2007;92:128-132.
19. Witt DR, Keena BA, Hall JG, Allanson JE: Growth curves for height in Noonan syndrome. Clin Genet 1986;30:150-153.
20. Ahmed ML, Foot AB, Edge JA, Lamkin VA, Savage MO, Dunger DB: Noonan's syndrome: abnormalities of the growth hor-mone/IGF-I axis and the response to treatment with human biosynthetic growth hormone. Acta Paediatr Scand 1991;80:446-450.
21. Noordam C, van der Burgt I, Sweep CG, Delemarrevan de Waal HA, Sengers RC, Otten BJ: Growth hormone (GH) secretion in children with Noonan syndrome: frequently abnormal without consequences for growth or response to GH treatment. Clin Endocrinol 2001;54:53-59.
22. Kim SO, Jiang J, Yi W, Feng GS, Frank SJ: Involvement of the Src homology 2-containing tyrosine phosphatase SHP2 in growth hormone signalling. J Biol Chem 1998;273: 2344-2354.
23. Yu C-L, Yong-Jiu J, Burakoff SJ: Cytosolic tyrosine dephosphorylation of STAT5. J Biol Chem 2000;275:599-604.
24. Chen Y, Wen R, Yang S, Schuman J, Zhang EE, Yi T, Feng G-S, Wang D: Identification of SHP2 as a Stat5a phosphatase. J Biol Chem 2003;278:16520- 16527.
25. Stofega MR, Herrington J, Billestrup N, Carter-Su C: Mutation of the SHP2 binding site in growth hormone (GH) receptor prolongs GH-promoted tyrosyl phosphorylation of GH receptor, JAK2, and STAT5B. Mol Endocrinol 2000;14:1338-1350.
26. Binder G, Neuer K, Ranke MB, Wittekindt NE: PTPN11 mutations are associated with mild growth hormone resistance in individuals with Noonan syndrome. J Clin Endocrinol Metab 2005;90:5377-5381.
27. Ferreira LV, Souza SAL, Arnhold IJP, Mendonca BB, Jorge AAL: PTPN11 mutations and response to growth hormone therapy in children with Noonan syndrome. J Clin Endocrinol Metab 2005;90:5156-5160.
28. Limal J-M, Parfait B, Cabrol S, Bonnet D, Leheup B, Lyonnet S, Vidaud M, Le Bouc Y: Noonan syndrome: relationships between genotype, growth, and growth factors. J Clin Endocrinol Metab 2006;91:300-306.
29. MacFarlane CE, Brown DC, Johnston LB, Patton MA, Dunger DB, Savage MO, Mc-Kenna WJ, Kelnar CJ: Growth hormone therapy and growth in children with Noonan's syndrome: results of 3 years' follow-up. J Clin Endocrinol Metab 2001;86:1953-1956.
30. Noordam C, van der Burgt I, Sengers RCA, Delemarrevan de Waal HA, Otten BJ: Growth hormone treatment in children with Noonan's syndrome: four year results of a partly controlled trial. Acta Paediatr 2001; 90:889-894.
31. Osio D, Dahlgren J, Albertsson Wikland K, Westphal O: Improved final height with long-term growth hormone treatment in Noonan syndrome. Acta Paediatr 2005;94: 1232-1237.
32. Kratz CP, Niemeyer CM, Castleberry RP, Cetin M, Bergsträsser E, Emanuel PD, Hasle H, Kardos G, Klein C, Kojima S, Stary J, Trebo M, Zecca M, Gelb BD, Tartaglia M, Loh ML: The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myeloproliferative disease. Blood 2005;106:2183-2185.
33. Giovannini L, Cavé H, Ferrero-Vacher C, Boutte P, Sirvent N: A new PTPN11 mutation in juvenile myelomonocytic leukaemia associated with Noonan syndrome. Acta Paediatr 2005;94:636-637.
34. Cheong JL, Moorkamp MH: Respiratory failure, juvenile myelomonocytic leukemia, and neonatal Noonan syndrome. J Pediatr Hematol Oncol 2007;29:262-264.
35. Chan RJ, Leedy MB, Munugalavadla V, Voorhorst CS, Li Y, Yu M, Kapur R: Human somatic PTPN11 mutations induce hemato-poietic-cell hypersensitivity to granulocyte-macrophage colony-stimulating factor. Blood 2005;105:3737-3742.
36. de Lange J, van den Akker HP, van den Berg H: Central giant cell granuloma of the jaw: a review of the literature with emphasis on therapy options. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007; 104:603-615.